NCT03590444View on ClinicalTrials.gov

Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 2, 2017

Primary Completion Date

April 2, 2018

Study Completion Date

June 2, 2018

Conditions
Diabetic Retinal Edema
Interventions
DRUG

Ranibizumab 0.5 MG/0.05 ML Intraocular Solution

"Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution"

Trial Locations (1)

1130

Hietzing Hospital, Vienna

All Listed Sponsors
lead

Hospital Hietzing

OTHER

NCT03590444 - Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser | Biotech Hunter | Biotech Hunter